This company has been marked as potentially delisted and may not be actively trading. Stealth BioTherapeutics (MITO) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period FDA delays decision on Stealth BioTherapeutics' rare genetic disorder drugApril 29, 2025 | reuters.comStealth faces another hurdle as FDA delays decision on Barth syndrome drugJanuary 24, 2025 | msn.comStealth BioTherapeutics Announces PDUFA Action Date Extension for Elamipretide to Treat Patients with Barth SyndromeJanuary 23, 2025 | prnewswire.comFDA AdCom votes in favour of Stealth’s Barth syndrome drugOctober 12, 2024 | msn.comSTEALTH BIOTHERAPEUTICS' BARTH SYNDROME NDA RECEIVES PRIORITY REVIEW DESIGNATIONMay 7, 2024 | prnewswire.comStealth BioTherapeutics to Present at JMP Citizens Life Sciences ConferenceMay 6, 2024 | prnewswire.comBolt Biotherapeutics IncApril 17, 2024 | money.usnews.comSTEALTH BIOTHERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR ELAMIPRETIDE FOR THE TREATMENT OF BARTH SYNDROMEApril 8, 2024 | prnewswire.comSonnet BioTherapeutics Holdings Inc.February 22, 2024 | wsj.comIovance Biotherapeutics Inc (IOVA)February 9, 2024 | investing.comBarinthus Biotherapeutics PLC ADR BRNSNovember 23, 2023 | morningstar.comLab Notes: Vittoria Biotherapeutics raises $15M; Madrigal adds to C-suiteNovember 17, 2023 | bizjournals.comIovance Biotherapeutics Inc IOVANovember 16, 2023 | morningstar.comSAB Biotherapeutics Inc SABSNovember 9, 2023 | morningstar.comCalidi Biotherapeutics Inc (CLDI)October 30, 2023 | investing.comStealth BioTherapeutics achieves target enrolment in PMM therapy trialSeptember 12, 2023 | msn.comStealth BioTherapeutics Completes Target Enrollment in Global Phase 3 NuPOWER Trial in Patients with Primary Mitochondrial MyopathySeptember 11, 2023 | benzinga.comAs Needham biotech struggles with FDA, patients with an ultra-rare disease are waitingSeptember 6, 2023 | bizjournals.comB-2 stealth bombers to return to flight after 5-month delayJune 2, 2023 | news.yahoo.comWealth with stealthMay 16, 2023 | dailymail.co.ukGlobal Mitochondrial Myopathy Diagnosis & Treatment Market Size by Type (itochondrial Myopathy Diagnosis) Forecast from 2023 to 2028March 27, 2023 | marketwatch.comChain Reaction raises $70M, emerges from stealth to launch chips designed to compute encrypted dataFebruary 25, 2023 | techcrunch.comWill Roper's Istari, Inc. emerges from stealth mode to transform digital engineering and accelerate Industry 4.0February 19, 2023 | finance.yahoo.comStealth BioTherapeutics Corp Announces Completion of MergerNovember 16, 2022 | finance.yahoo.comTrading was temporarily halted for "MITO" at 07:11 PM with a stated reason of "News pending."November 16, 2022 | marketbeat.comStealth BioTherapeutics Announces SBT-272 Data Updates and Orphan Drug Designation for the Treatment of Amyotrophic Lateral Sclerosis (ALS)November 1, 2022 | finance.yahoo.comAs Trump Org trial looms, lawyers to look out for 'stealth jurors'October 27, 2022 | news.yahoo.comStealth BioTherapeutics Corp to Hold Extraordinary General Meeting of ShareholdersOctober 7, 2022 | finance.yahoo.comStealth BioTherapeutics to Participate in Upcoming Ultra-Rare Disease EventsSeptember 15, 2022 | finance.yahoo.comShort Volatility Alert: Stealth BioTherapeutics CorpAugust 5, 2022 | msn.comBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Stealth BioTherapeutics Corp (Nasdaq - MITO), Romeo Power, Inc. (NYSE - RMO), One Medical (Nasdaq - ONEM), Hanger, Inc. (NYSE - HNGR)August 1, 2022 | benzinga.comStealth BioTherapeutics To Be Taken Private In All-cash DealAugust 1, 2022 | nasdaq.comStealth BioTherapeutics Corp Enters Definitive Agreement for Going Private TransactionAugust 1, 2022 | finance.yahoo.comMITO: Stealth BioTherapeutics Considering Offer, While Progress ContinuesJuly 26, 2022 | finance.yahoo.comStealth BioTherapeutics Gets Buyout OfferJune 28, 2022 | marketwatch.comStealth Bio gains after non-binding buyout offerJune 27, 2022 | seekingalpha.comStealth BioTherapeutics Board Receives Preliminary Proposal LetterJune 27, 2022 | nasdaq.comStealth BioTherapeutics Corp Announces Receipt of Preliminary Non-Binding ProposalJune 27, 2022 | finance.yahoo.comTrading was temporarily halted for "MITO" at 06:06 AM with a stated reason of "News pending."June 27, 2022 | marketbeat.comStealth Granted Pre-NDA Meeting For Elamipretide To Treat Barth SyndromeJune 14, 2022 | markets.businessinsider.comStealth Bio rises on pre-NDA meeting for candidate targeting rare heart conditionJune 14, 2022 | seekingalpha.comStealth BioTherapeutics Granted Pre-NDA Meeting for Elamipretide as a Potential Treatment for Barth SyndromeJune 14, 2022 | finance.yahoo.comHealthcare Breakthroughs: NVAX, MITO, LMLLF, NMLSF; Life Sciences Leaders Report Latest Advances in Vaccines, Novel Therapeutics for Autism, Neurodegenerative, Oncology, and GlaucomaJune 8, 2022 | finance.yahoo.comWhy Stealth BioTherapeutics Shares Are Surging Today?June 8, 2022 | benzinga.comStealth BioTherapeutics Presents New SBT-272 Data Demonstrating Improvement in Upper Motor Neuron Function in ALS Disease Model at Keystone Neurodegeneration SymposiumJune 8, 2022 | finance.yahoo.comStealth Bio's elamipretide gets EMA orphan drug status for muscle disorderMay 31, 2022 | seekingalpha.comStealth BioTherapeutics Receives Orphan Drug Designation from the European Medicines Agency for Elamipretide for the Treatment of Myopathic Mitochondrial DNA Depletion SyndromeMay 31, 2022 | finance.yahoo.comStealth BioTherapeutics Announces Data from the Phase 2 ReCLAIM-2 Study of Elamipretide in Geographic Atrophy at the Clinical Trials at the Summit Meeting 2022May 23, 2022 | finance.yahoo.comStealth Bio climbs on FDA’s Orphan Drug status for lead asset in muscular disorderMay 12, 2022 | seekingalpha.comMITO: Positive Data Despite Miss for MITOMay 3, 2022 | msn.com Get Stealth BioTherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MITO and its competitors with MarketBeat's FREE daily newsletter. Email Address MITO Media Mentions By Week MITO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MITO News Sentiment▼0.000.73▲Average Medical News Sentiment MITO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MITO Articles This Week▼10▲MITO Articles Average Week Get Stealth BioTherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MITO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CRBP News Today PLRX News Today ANIX News Today VTYX News Today XBIT News Today ORMP News Today CNTX News Today BMEA News Today GALT News Today CLYM News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MITO) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWill May start the next "Great Depression?"You probably haven't heard about this yet... But this could be the biggest wealth building opportunity of t...Behind the Markets | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stealth BioTherapeutics Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share Stealth BioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MITO Stock Free MITO Stock Alerts